Results 121 to 130 of about 4,730,453 (227)

Novel targets in headache: A narrative review

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background This narrative review summarizes novel applications for the use of calcitonin gene‐related peptide (CGRP)‐targeted therapies that go beyond migraine, the latest updates with respect to targeting pituitary adenylate cyclase‐activating peptide (PACAP) as therapeutic in migraine, as well as exploring other more recently ...
Adriana Della Pietra, Peter J. Goadsby, Carolina Oldoni, Stephen Silberstein, Fred Cohen, Simon Akerman   +5 more
wiley   +1 more source

Reducing the Probability of False Positive Research Findings by Pre-Publication Validation - Experience with a Large Multiple Sclerosis Database [PDF]

, 2007
*Objective* We have assessed the utility of a pre-publication validation policy in reducing the probability of publishing false positive research findings.
Moritz M. Heinz, Martin M. Daumer, Katja K. Ickstadt, Siegfried S. Schach, Ulrike U. Held, George G. Ebers   +5 more
core  

Management of Non‐Plaque‐Induced Gingival Conditions: A Systematic Review—Part 2: Inflammatory and Immune Conditions; Neoplasms; and Gingival Pigmentation

Journal of Clinical Periodontology, EarlyView.
ABSTRACT Aims This systematic review assesses current evidence on the management of non‐plaque (dental biofilm)‐induced gingival diseases and conditions (NPIGDs), including (i) inflammatory and immune conditions, (ii) neoplasms and (iii) gingival pigmentations.
Maria Clotilde Carra, Cecile Wasielewski, Bruno Špiljak, Maja Sabalić‐Schoener, Sebastien Jungo, Ivan Alajbeg   +5 more
wiley   +1 more source

Male genital lichen sclerosus

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Male genital lichen sclerosus is driven by chronic, occluded exposure of susceptible genital epithelium to urine, rather than infection or autoimmunity. This review synthesizes clinical, anatomical and molecular evidence showing how microincontinence and occlusion initiate inflammation, fibrosis and carcinogenesis, and explains the curative effect of ...
Georgios Kravvas, Rory Barry, Richard E. Watchorn, Christopher B. Bunker   +3 more
wiley   +1 more source

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

, 2012
Background The anti-CD52 monoclonal antibody alemtuzumab reduced disease activity in a phase 2 trial of previously untreated patients with relapsing-remitting multiple sclerosis.
Hartung, H.P., Barkhof, F., Brinar, Vesna V., Margolin, David H., Havrdova, E., Weiner, H.L., Stojanovic, M., Ertik, Bella I., Cohen, J.A., Havrdova, Eva, Arnold, D.L., Selmaj, K.W., Cohen, Jeffrey A., Hartung, Hans-Peter, Stojanovic, Miroslav, McCombe, Pamela, Margolin, D.H., Compston, D. Alastair S., Giovannoni, G., Coles, Alasdair J., CARE-MS I investigators, Panzara, M.A., Fisher, E., Confavreux, Christian, Fisher, Elizabeth, Brinar, V.V., Ertik, B.I., Compston, D., Fox, E.J., Confavreux, C., Selmaj, Krzysztof W., Panzara, Michael A., Arnold, Douglas L., Lake, Stephen L., Lake, St.L., Weiner, Howard L., Giovannoni, Gavin, Fox, Edward J., Coles, A.J.   +38 more
core   +1 more source

Targeted therapies in pemphigus vulgaris: Emerging horizons beyond rituximab

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Rituximab‐refractory pemphigus vulgaris is driven by B‐cell repopulation, plasma‐cell persistence, IgG4 autoantibodies and anti‐drug antibodies. This review evaluates five emerging targeted classes acting at successive steps of disease: next‐generation anti‐CD20 antibodies, DSG3‐CAAR T cells, BTK inhibitors, BAFF/APRIL inhibitors and FcRn antagonists ...
Rhea Ahuja, Dedee Murrell
wiley   +1 more source

Estimation of annual probabilities of changing disability levels in Australians with relapsing-remitting multiple sclerosis

, 2019
BACKGROUND: Transition probabilities are the engine within many health economics decision models. However, the probabilities of progression of disability due to multiple sclerosis (MS) have not previously been estimated in Australia.
Ahmad, Hasnat, Broadley, Simon, Lucas, Robyn M, van der Mei, Ingrid, Taylor, Bruce, Clarke, Philip M, Palmer, Andrew J, Valery, Patricia, Lechner-Scott, Jeannette, Ponsonby, Anne-Louise, Dwyer, Terry, Dear, Keith, Blizzard, Leigh, Simpson, Steve, et al.   +14 more
core   +1 more source

Understanding the Reproductive Life Planning Experiences of People With Disabilities in Ontario, Canada: A Qualitative Exploration

Perspectives on Sexual and Reproductive Health, EarlyView.
ABSTRACT Introduction Reproductive life planning can be a valuable component of reproductive health promotion. However, little is known about attitudes, desires, and intentions regarding pregnancy among people with disabilities. This exploratory qualitative study aimed to understand the reproductive life planning experiences of women and gender‐diverse
Momina Khan, Hilary K. Brown, Yona Lunsky, Lesley A. Tarasoff   +3 more
wiley   +1 more source

Oral available agents in the treatment of relapsing remitting multiple sclerosis an overview of merits and culprits

, 2013
Jan Thöne, Gisa Ellrichmann Department of Neurology, St Josef-Hospital Bochum, Ruhr-University Bochum, Bochum, Germany Abstract: Multiple sclerosis (MS) is a chronic immunological disease of the central nervous system characterized by early ...
Thöne J, Ellrichmann G
core  

Migration and infectious disease in the etiology of multiple sclerosis: A case-control study

, 1989
Epidemiological study on multiple sclerosis risk of migration from South to North ...
Altobelli A., Italian Multiple Sclerosis Study Group, GRANIERI, Enrico Gavino Giuseppe   +2 more
core